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Soluble guanylyl cyclase (sGC), the key transducer of
nitric oxide (NO) signalling in vascular smooth muscle
cells and platelets, exists in two redox forms: the NO-sen-
sitive ferrous heme-iron (Fe(II)) form and a NO-insensi-
tive oxidized form containing the ferric heme-iron
(Fe(III)). HMR1766 (proposed INN ataciguat sodium)
reversibly stimulates the oxidized form of sGC (crude and
purified) in various species and organs to about 10 to 30
% of the maximal activity achieved with NO donors.
Acute treatment with HMR1766 has anti-ischemic (acute
coronary stenosis) and anti-thrombotic (coronary throm-
bosis) effects in dog models at doses that did not influ-
ence arterial blood pressure or other hemodynamic
parameters.
However, the role of oxidized sGC under chronic patho-
physiological conditions is poorly understood. We there-
fore investigated the chronic activation of the oxidized
sGC by HMR1766 as a therapeutic strategy to inhibit vas-
cular and endothelial dysfunction, myocardial hypertro-
phy and survival in various animal models.
Compared to wild-type mice, placebo-treated apolipopro-
tein-deficient (ApoE-/-) mice fed with a high fat diet
develop endothelial dysfunction, as indicated by an
impaired endothelium-dependent vasodilatation, and
severe atherosclerotic lesion formation in the aorta. Long-
term treatment with HMR1766 containing chow (6 and
15 weeks) significantly reduced atherosclerotic plaque
formation and markedly improved endothelium-depend-
ent vasodilatation.
Diabetes mellitus is associated with an increased throm-
boembolic risk via activation of circulating platelets as
well as the development of endothelial and vascular dys-
function. Both effects have been attributed to a lack of
nitric oxide (NO) bioavailability and/or reduced sensitiv-
ity of sGC for NO. A single intravenous injection of strep-
tocotozine (STZ) to rats induced type-I diabetes and
attenuated NO-stimulated sGC activity isolated from
aorta as compared to the placebo injected control group.
The HMR1766-stimulated sGC activity was not different
between both groups. Chronic treatment of STZ diabetic
rats with HMR1766 starting 2 weeks after STZ normalized
platelet activation as measured by a reduction of P-selec-
tin expression and an increase in platelet vasodilator-stim-
ulated phosphoprotein (VASP)-phosphorylation.
Activation of sGC by HMR1766 normalized vascular dys-
function (sensitivity of vascular smooth muscles to con-
strictors) and restored endothelium-dependent relaxation
in isolated aortic rings from control and placebo-treated
STZ rats.
Spontaneously hypertensive rats (SHR) develop endothe-
lial dysfunction (impairment of endothelium-dependent
relaxation) and begin to die from cardiovascular compli-
cations at approximately 15 months of age. Long-term
treatment with HMR1766 starting at the age of 15 months
significantly improved endothelial dysfunction in iso-
lated aortic rings from control and placebo-treated SHR
and significantly extended lifespan.
The NO-cGMP pathway also plays a pivotal role in the
pathogenesis of pulmonary arterial hypertension (PAH).
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Four weeks after a single injection of monocrotaline,
which induces pulmonary arterial endothelial injury, rats
develop progressive pulmonary hypertension, with severe
right ventricular hypertrophy and mortality of more than
50% within 4–6 weeks. HMR1766, chronically adminis-
tered after the onset of PH (day 14 to 28), reduced right
ventricular pressure, right ventricular hypertrophy and
significantly improved survival.
In conclusion, the present data obtained with HMR1766,
which activates preferably the oxidized form of sGC, sug-
gest an important role of oxidized sGC in endothelial, vas-
cular and thrombocyte dysfunction. Chronic HMR1766
treatment improves endothelial function and reduces
atherosclerosis in ApoE-/- mice, normalizes platelet activa-
tion and restores endothelial and vascular function in
type-I diabetic rats, improves endothelial dysfunction and
survival in old SHR, and improves vascular remodelling,
hemodynamics and survival in rats with pulmonary
hypertension. Therefore, HMR1766 represents a promis-
ing agent for prevention and treatment of atherosclerosis
and pulmonary hypertension.Page 2 of 2
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